mNSCLC Clinical Data

GIVE MORE PATIENTS A KEY

ONLY ANTI–PD-1 APPROVED FIRST
LINE
AS COMBINATION THERAPY AND MONOTHERAPY
FOR APPROPRIATE PATIENTS WITH mNSCLC

KEYTRUDA® (pembrolizumab) for Metastatic Non-Small Cell Lung Cancer

FIRST-LINE COMBINATION THERAPY: KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). This indication is approved under accelerated approval based on tumor response rate and progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

FIRST-LINE MONOTHERAPY: KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

PD-1 = programmed death receptor-1; mNSCLC = metastatic NSCLC; PD-L1 = programmed death ligand 1; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase.